Malignant Pleural Mesothelioma: Treatment Patterns and Outcomes from the Spanish Lung Cancer Group

Rare thoracic malignancies, those with an incidence lower than 6 per 100,000 as a threshold of rarity, include epithelial tumors of the trachea, thymus and malignant pleural mesothelioma (MPM). Foremost among these rare tumors is mesothelioma, accounting for 2.1 cases per 100,000 people per year [1]. While we are witnessing years of exciting progress for lung cancer patients, very few advances have been made in MPM since the approval of pemetrexed in 2004 [2]. Not surprisingly, life expectancy of MPM remains suboptimal with a median overall survival (OS) of less than 1  year and 5-year OS of approximately 5% [1].

Source: Lung Cancer - July 1, 2020 Category: Cancer & Oncology Authors: J Remon, E Nadal, M D ómine, J Ruffinelli, Y García, JC Pardo, R López, A Cilleruelo, R García-Campelo, P Martín, O Juan, JL González-Larriba, M Provencio, E Olmedo, S Ponce, D Cumplido, C Barenys, M Majem, B Massutti, D Rodriguez-Abreu, R Porta, MA Source Type: research